The most visible construction project in America is back in the news with a federal appeals court affirming a preliminary injunction against above-ground construction on the new ballroom at the White House. The court found that the president had exceeded
The opportunity to make a substantial investment in a private company can be exciting — it offers the potential to share in the rapid growth of the company and may permit the investor to participate on the company’s governance team.
Every state gives contractors, subcontractors, and suppliers some form of lien right when they aren’t paid for work that improves real property. But Virginia’s version of this tool stands out from most other states in several important ways. If you
On July 23, 2026, the Consumer Financial Protection Bureau (CFPB) updated its Equal Credit Opportunity Act (ECOA) Baseline Review Procedures. Notably, the updates were issued just two days after the final amendments to Regulation B, the regulation implementing ECOA,
A federal judge in Houston has struck down the race-based aspects of two local contracting programs intended to remedy past discrimination as unconstitutional. The City of Houston’s program set goals for the percentage of contracts awarded to minority-owned businesses and
Trade fraud takes center stage and continues to expand as a priority for the Department of Justice (DOJ).
On July 14, 2026, the DOJ announced its plans to expand trade fraud enforcement by creating the Global Trade & Commerce Enforcement
The Equal Employment Opportunity Commission (EEOC) is positioned for another rescission mission. Recall that recently, the EEOC rescinded the 2024 Enforcement Guidance on Harassment in the Workplace and two affirmative action documents. The commission’s apparent next mission relates to
We’ve been waiting on this one for three years. If you’ve frequented this blog, you know three years is basically an eternity in Food and Drug Administration (FDA) years but a blink of an eye in cannabis-and-psychedelics-regulatory years. On July
In a decisive reversal, the Federal Circuit handed Boston Scientific Corporation a complete victory in Board of Regents of the University of Texas System v. Boston Scientific Corp., vacating a jury verdict that had found Boston Scientific’s drug-eluting coronary
